Nippon India Nifty Pharma ETF delivered a 13.6% return over the past three months, leading the index ETF category. The fund has consistently outperformed its benchmark, with a 20.9% three-year CAGR. As a sectoral fund, it carries concentrated risks tied to the pharmaceutical industry, and investors should weigh this against broader market index funds.
The Nippon India Nifty Pharma ETF has emerged as a standout performer in the index ETF space, recording a 13.6% return over the three-month period ending in August 2026. This performance has placed it at the top of the category, outshining several other index-linked schemes. The fund’s recent success is not an isolated event; it has demonstrated a history of consistent outperformance against the Nifty Pharma Total Returns Index (TRI) over both one-year and three-year horizons.
The fund’s long-term track record is marked by a three-year compounded annual growth rate (CAGR) of approximately 20.9%. This sustained growth highlights the sector's recovery and expansion over the past few years. With an asset base of approximately ₹1,622 crore and a low expense ratio of 0.21%, the fund provides a cost-effective way for investors to gain exposure to the companies that make up the Nifty Pharma Index.
Understanding the Sectoral Risk
While the fund’s returns are notable, it is important for investors to understand that this is a sectoral ETF, not a broad market index fund like a Nifty 50 ETF. A sectoral fund puts all its money into a single industry. This means the fund's value is entirely dependent on the health of the pharmaceutical sector. If the pharma industry faces a downturn, the fund does not have the cushion of other sectors like banking, IT, or auto to balance the losses.
Pharmaceutical companies are subject to unique pressures, including strict regulatory scrutiny, unpredictable drug approval cycles from agencies like the US FDA, and pricing controls imposed by governments in various export markets. These factors can lead to high volatility, which is why the fund carries a 'Very High' riskometer rating. Unlike broad market funds that diversify risk across the entire economy, this ETF is a concentrated bet on a single industry.
What Investors Should Monitor
For those looking at this fund, the most important monitorables are sector-specific developments. Investors should keep a close watch on trends such as export volumes, raw material costs, and changes in health policies that impact drug pricing. Any major regulatory or legal challenge faced by key index constituents can directly impact the fund's Net Asset Value (NAV). Additionally, while ETFs are designed to track their underlying index, tracking error—the slight difference between the fund's returns and the actual index performance—is another factor to observe over time.